Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2003
03/20/2003WO2003022849A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003WO2003022845A1 Pyrazolo-pyridines for the treatment of herpes infections
03/20/2003WO2003022842A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003WO2003022839A1 Tetrahydropyran derivatives and their use as therapeutic agents
03/20/2003WO2003022836A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors
03/20/2003WO2003022835A1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
03/20/2003WO2003022833A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022832A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022824A1 Oxazolidinone and/or isoxazoline as antibacterial agents
03/20/2003WO2003022821A1 Heterocycle derivative having 20-hete-producing enzyme inhibitory activity
03/20/2003WO2003022815A1 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
03/20/2003WO2003022814A1 Indole derivatives
03/20/2003WO2003022813A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
03/20/2003WO2003022809A2 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
03/20/2003WO2003022804A2 Method for the preparation of crystalline tetrahydrobenzothiepines
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022799A1 Ccr-3 receptor antagonists v
03/20/2003WO2003022797A1 Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
03/20/2003WO2003022787A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003WO2003022310A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003WO2003022309A1 Remedies for allergic diseases
03/20/2003WO2003022305A1 Method for treating coumarin-induced hemorrhage
03/20/2003WO2003022302A2 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
03/20/2003WO2003022286A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
03/20/2003WO2003022285A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003WO2003022279A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines and a tiotropium salt
03/20/2003WO2003022277A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
03/20/2003WO2003022276A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003WO2003022275A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines
03/20/2003WO2003022272A1 Appetite-stimulating agents and remedies for anorexia
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022258A1 Aryloxypropylamines as chemosensitizing agent in the treatment of cancer
03/20/2003WO2003022246A1 Treating effects of excessive reactive oxygen species
03/20/2003WO2003022243A2 Sustained release of microcrystalline peptide suspensions
03/20/2003WO2003022218A2 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
03/20/2003WO2003022217A2 Treatment of excessive radiation (e.g. sunburn) exposure
03/20/2003WO2003022216A2 Biaryl substituted purine derivatives as potent antiproliferative agents
03/20/2003WO2003022209A2 Crystalline forms of valacyclovir hydrochloride
03/20/2003WO2003011241A8 Utilization of creatinine and/or creatinine derivatives in cosmetic and dermatological preparations
03/20/2003WO2003004466A3 Dye-sulfenates for dual phototherapy
03/20/2003WO2002102808A3 (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR
03/20/2003WO2002102344A3 No-synthase inhibitor and use thereof
03/20/2003WO2002100845A8 Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/20/2003WO2002099075A3 Prmts as modifiers of the p53 pathway and methods of use
03/20/2003WO2002098363A3 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
03/20/2003WO2002096354A3 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
03/20/2003WO2002094768A3 Aza hydroxylated ethyl amine compounds
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002083113A3 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
03/20/2003WO2002081686A3 Nucleic acids binding a neuropeptide
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002077184A3 Oligonucleotide conjugates
03/20/2003WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications
03/20/2003WO2002074045A3 Production of pancreatic islet cells and delivery of insulin
03/20/2003WO2002067951A3 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
03/20/2003WO2002067865A3 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
03/20/2003WO2002062323A3 Use of mglur5 antagonists for the treatment of pruritic conditions
03/20/2003WO2002053171A3 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity
03/20/2003WO2002051810A3 Integrin receptor ligands
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002046189A3 Aryl ether substituted imidazoquinolines
03/20/2003WO2002030444A3 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
03/20/2003WO2002028408A3 Compositions and methods for the transport of biologically active agents across cellular barriers
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2002012245B1 Azabicyclic derivatives and their therapeutic use
03/20/2003WO2002012188B1 Indole compounds useful for the treatment of cancer
03/20/2003WO2002004520A3 Transporters and ion channels
03/20/2003WO2001087913A9 Method for treating retinal degeneration with purinergic receptor agonists
03/20/2003WO2001072341A3 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
03/20/2003US20030056240 Transgenic animal model for use in the treatment of diabetes
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055266 Small molecule modulators of G protein-coupled receptors
03/20/2003US20030055265 Oxazole derivatives
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055246 Serine protease inhibitors
03/20/2003US20030055245 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
03/20/2003US20030055111 For use in preparation of medicaments for the treatment of tumors and rheumatoid arthritis
03/20/2003US20030055101 Use of statins to inhibit formation of osteoclasts
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055088 Aryl substituted pyridines and the use thereof
03/20/2003US20030055086 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
03/20/2003US20030055083 Method of providing an antihistaminic effect in a hepatically impaired patient
03/20/2003US20030055080 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
03/20/2003US20030055072 Methods of inhibiting Pin1-associated states using a fredericamycin a compound
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055061 Therapy of disease or condition which is caused by a disorder of the serotonin system by administering 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives, and their acid addition salts
03/20/2003US20030055060 Imidazo-triazine derivatives as ligands for GABA receptors
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055051 Having anti- inflammatory effect, which is less irritant, which has high safety and storage stability
03/20/2003US20030055050 CRF receptor antagonists and methods relating thereto
03/20/2003US20030055046 Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055042 Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
1 ... 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 ... 1564